Skip to content
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Issuance page – warrants of series TO7
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
Menu
About Prolight
Market
Partnerships
Board of Directors and Management
Clinical Advisory Board
History
Cutting-edge technology
Vision & strategy
Products
Psyros™
MicroFlex
Patents
Investors
Press releases
Financial reports
CEO comment
Financial calendar
Stock information
AGM
Shareholders
Key figures
Corporate governance
Prospectus
Issuance page – warrants of series TO7
Media
Press releases
Investor letters
Media gallery
Presentations
Articles
Contact us
EN
SV
Press releases
Category
All
Regulatory
Non-Regulatory
Interim
Annual
Year
All
2024
2023
2022
2024
2024-10-21 15:10
Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million
Regulatory
MAR
2024-10-15 08:00
Last day of trading with warrants of series TO7 in Prolight Diagnostics is today, October 15, 2024
Regulatory
2024-10-14 16:05
Members of the Board of Directors, management and external investors have undertaken to exercise warrants of approximately SEK 4.3 million, corresponding to 32.9 percent of outstanding warrants of series TO7
2024-10-09 08:00
Prolight obtains patent potentially representing a new business opportunity
2024-10-07 09:45
The exercise period for warrants of series TO7 in Prolight Diagnostics begins today
Regulatory
2024-10-03 18:45
The exercise price for the warrants of series TO7 in Prolight Diagnostics has been determined to SEK 0.12 per share
Regulatory
2024-09-30 15:40
Prolight Diagnostics publishes investor letter for september 2024
2024-09-26 08:30
Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting
Regulatory
2024-09-25 14:30
Prolight conducts business review at FlexMedical Solutions
2024-08-30 13:48
Emergers publishes an updated analysis on Prolight Diagnostics, reaffirming a justified value of 1.1-1.2 SEK per share
Next
